17 October 2025
17 October 2025
The AAM’s Giuseppe Randazzo warns that the generics business could become unsustainable in the future if the market dynamics do not change.
Novo Nordisk will now run a Phase III trial for zaltenibart in the rare blood disorder, PNH.
The investment is part of AstraZeneca’s wider $50bn outlay to bolster manufacturing in the US.
The partnership is in accordance with a White House Executive Order aimed at enhancing affordable access
Adcytherix has set a target to file for an IND and clinical trial applications in Canada, the UK, and the EU by the end of 2025.
With a legacy rooted in global scientific excellence, Sweden is quietly building one of Europe’s most dynamic biotech ecosystems - despite lacking a big pharma anchor and facing persistent funding gaps.
Merging industry-leading business intelligence & award-winning journalism, this is an unrivalled opportunity for engagement with B2B professionals across a network of 40+ leading media websites.
Steer your business strategy with key data and insights from our latest market research reports and company profiles. Not ready to buy? Start small by downloading a sample report first.
Give your business an edge with our leading industry insights.
